Sionnatx
2 known investors
Sionna Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule medicines for cystic fibrosis by stabilizing the CFTR protein's NBD1 domain to correct defects from the F508del mutation. It is also building a portfolio of complementary CFTR modulators intended to work with its NBD1 stabilizers to restore CFTR function in CF patients.
Biotech
Investors Β· 2
Frequently asked questions
- What does Sionnatx do?
- Sionna Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule medicines for cystic fibrosis by stabilizing the CFTR protein's NBD1 domain to correct defects from the F508del mutation. It is also building a portfolio of complementary CFTR modulators intended to work with its NBD1 stabilizers to restore CFTR function in CF patients.
- Who are Sionnatx's investors?
- Sionnatx's investors include Atlas Venture, OrbiMed.